When: Price pulls back to $250-260

Then: Deploy one-third of new capital

When: Price pulls back to $235

Then: Deploy final one-third of new capital

When: Pullback to $258-263 with RSI reset toward 45-50 and fresh MACD positive crossover

Then: Re-rate from HOLD to OVERWEIGHT

Maintain current position sizing, discipline, and trading parameters; do not loosen stops or reduce trim discipline; HARVEST 10-20% of position at $280-$290 levels rather than adding or tightening risk parameters

• Forward P/E of 22.6x is anchored to consensus EPS estimate of $12.31, which is subject to revision—treating this as 'largely de-risked' is circular logic that has preceded every stock that subsequently missed in this cycle
• Balance sheet has materially deteriorated: total debt rose from roughly $36.6 billion to $49 billion in 18 months (34% increase), with $96.7 billion in goodwill and intangibles and tangible book value negative $11.74 billion, leaving minimal margin for impairment events
• The $14.6 billion Caplyta acquisition (7x sales) represents a single concentrated bet on CNS franchise with direct goodwill impairment risk if any readout disappoints
• There are seven independent headwinds stacking against the bull case—not one contingent tail risk—including Stelara biosimilar erosion, talc litigation case-by-case tail risk, IRA Medicare price negotiation expansion, 40% FX exposure to dollar strengthening, rising MedTech competitive intensity, post-Caplyta leverage reducing M&A flexibility, and valuation compression at the high end of historical P/E range
• Pipeline success is being priced at upper-end historical success rates when Phase 2+ attrition historically runs 80-90%, making pipeline optionality the 'most dangerous argument' in the bullish case
• Technical entry is poor: stock at upper Bollinger band, RSI at 65.9, 99% of 52-week high, after running 56.5% TTM (vs S&P 19.1%)—mean reversion happens more often than not from these levels
• Tightening stop from $233 to $240 represents a 7% reduction in downside protection per share at exactly the wrong entry point, reducing capital protection when volatility risk is elevated

→ vs aggressive: The '43% earnings recovery is largely de-risked' framing is circular logic—consensus was saying the same about every stock that subsequently missed in this cycle, and forward EPS of $12.31 is not a guaranteed number but a consensus estimate subject to revision

→ vs aggressive: The forward P/E of 22.6x on a consensus estimate is not a solid valuation anchor when inputs are still in motion and $14.6 billion of goodwill tied to Caplyta is exposed to CNS pipeline disappointment

→ vs aggressive: The 'downside requires multiple things to break simultaneously' argument is factually wrong—there are seven independent headwinds, and the conservative view needs only one to materialize while the bullish view needs all seven to clear

→ vs aggressive: Pipeline 'real, diversified, and already validating' claims are overstated—Tremfya is still scaling, Carvykti faces competitive pressure from etentamig, Caplyta is a single concentrated bet at 7x sales, and R&D spend of $14.7 billion annually means realistic Phase 2+ attrition rates of 80-90% will produce significant non-approved outcomes

→ vs aggressive: Tightening the stop from $233 to $240 gives up $7 per share in capital protection when the stock is at 99% of 52-week high—this is the opposite of what a risk manager should do at an extended entry point

→ vs aggressive: The bullish case conflates near-term momentum narrative (UBS target, breakout, defensive compounder status) with structural thesis strength—current 56.5% TTM return versus S&P 19.1% is precisely the environment where disciplined trim discipline should be applied, not relaxed

→ vs neutral: The 'wait for pullback' advice is not perfectionism but basic risk management—a 3% pullback to the 10 EMA materially improves risk/reward without changing the structural thesis and is the appropriate re-entry zone

HOLD; keep stop at 233; adjust trim levels to 278-288 with first tranche at 278; do not add above 271; wait for pullback to 10 EMA (270.90) or Bollinger mid (266.68) for new capital

• Forward P/E of 22.6x is reasonable for a 25.7% ROE business, but 43% earnings recovery and forward EPS of 12.31 are consensus estimates subject to revision
• Fortress balance sheet is real ($16.9B FCF, 1.56x dividend coverage, $20B cash) but leveraged: debt rose from $36.6B to $49B in 18 months, tangible book negative $11.74B, Caplyta goodwill at 7x sales
• Downside risks (Stelara erosion, MedTech competition, FX, IRA pricing, Caplyta goodwill) are not fully independent variables but are not equally likely to materialize
• Stock at upper Bollinger band (278.43 vs 278.92) with RSI 65.9 after 56% TTM return; adding at current levels is chasing, not aggressiveness
• Q2 2026 6.6% revenue growth validates post-Stelara transition better than feared, but 80-90% Phase 2 attrition rate remains relevant with $14.7B annual R&D spend
• Macro tailwind is real: zero Fed cuts priced at 89%, 8% recession odds (Goldilocks-for-defensives regime), but defensive flows are partially responsible for 56% return and already in price
• Tightening stop from 233 to 240 would place it in middle of consolidation zone (258-262); current 233 stop just below 200 SMA at 233.10 is correct
• Trim range adjusted slightly to 278-288 (from 280-290) given stock already at 278.43, with first tranche at 278 on confirmed upper-band breakout

→ vs aggressive: Tightening stop from 233 to 240 is wrong; places stop in consolidation zone between 258-262, making it more likely to trigger on routine volatility rather than protecting capital through drawdown

→ vs aggressive: Calling pullback entries to 10 EMA (270.90) or Bollinger mid (266.68) 'perfectionism' is incorrect; buying at upper Bollinger band (278.43) is chasing, not sound tactical choice

→ vs aggressive: Bull/bear asymmetry framing is structurally wrong; headwinds (Stelara erosion, MedTech competition, FX, IRA pricing, Caplyta goodwill) are not fully independent and bear case does not require everything to break simultaneously

→ vs aggressive: Balance sheet 'fortress' characterization is too dismissive; $49B debt and negative tangible book ($11.74B) do compress error tolerance even if appropriate for AAA pharma

→ vs conservative: Trim level of 280-290 is slightly too high given stock already at 278.43 and upper Bollinger at 278.92; adjusted to 278-288 with first tranche at 278

→ vs conservative: Has underweighted macro tailwind: zero Fed cuts at 89%, 8% recession odds create Goldilocks-for-defensives regime actively working in JNJ's favor

→ vs conservative: Slightly overstates independence of headwinds; risks are correlated to some degree, though not all equally likely to materialize